Clinical Trials

Accrual Status
Limit to SWOG Trials

1044 Results

Closed
Phase
Accrual
28%
Published
SWOG Clinical Trial Number
SWOG-8922
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8933

Evaluation of Piroxantrone in Pancreatic Adenocarcinoma

Activated
09-01-1990
Closed
09-15-1991
Closed
Phase
Accrual
76%
Published
SWOG Clinical Trial Number
SWOG-8945
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
SWOG-9037 (CALGB-9196)
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
72%
Published
SWOG Clinical Trial Number
SWOG-8911
Closed
Phase
Accrual
45%
Published
SWOG Clinical Trial Number
SWOG-8834

A Phase II Evaluation of Fazarabine in Central Nervous System Tumors

Research Committee(s)
Brain Cancer
Activated
07-01-1990
Closed
12-01-1991
Closed
Phase
Accrual
83%
Published
SWOG Clinical Trial Number
SWOG-8930
Closed
Phase
Accrual
3%
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8957
Closed
Phase
SWOG Clinical Trial Number
SWOG-8947

Central Lymphoma Serum Repository Protocol

Research Committee(s)
Lymphoma
Activated
04-15-1990
Closed
Phase
Accrual
23%
SWOG Clinical Trial Number
SWOG-8939

Evaluation of Merbarone in Colorectal Cancer

Activated
04-15-1990
Closed
07-15-1991
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8929
Closed
Phase
Accrual
74%
SWOG Clinical Trial Number
SWOG-8954

Evaluation of the L-17M Protocol in the Management of Patients with Lymphoblastic Lymphoma

Research Committee(s)
Lymphoma
Activated
04-15-1990
Closed
05-15-1997
Closed
Phase
SWOG Clinical Trial Number
SWOG-8859 (INT-0110)
Closed
Phase
Accrual
70%
Published
SWOG Clinical Trial Number
SWOG-8902
Closed
Phase
Accrual
90%
Published